1
|
Bordas-Martinez J, Miedema JR, Mathot BJ, Seghers L, Galjaard RJH, Raaijmakers MH, Aalbers AM, Wijsenbeek M, Molina-Molina M, Hellemons ME. Outcomes of lung transplantation in patients with telomere-related forms of progressive fibrosing interstitial lung disease pulmonary fibrosis: A systematic review. JHLT OPEN 2024; 3:100054. [PMID: 40145120 PMCID: PMC11935452 DOI: 10.1016/j.jhlto.2024.100054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 03/28/2025]
Abstract
Background Lung transplantation (LTX) is the last life-extending option for patients with progressive fibrosing interstitial lung diseases (fILD). Between 12% and 71% of patients with fILD are patients with underlying telomere-dysfunction (trILD) related to pathogenic telomere-related gene (TRG) variants and/or short telomere length. TrILD patients tend to have earlier disease onset, faster progression, and worse prognosis causing them to be referred for LTX more often. Regarding LTX outcomes in trILD, there are contradictory reports on patient and graft survival, as well as numerous other outcomes. There is no consensus on whether trILD is associated with poorer outcomes after LTX and what considerations regarding candidacy are appropriate. Methods We aimed to systematically review LTX outcomes of patients with trILD in comparison to those with non-trILD. Results A systematic literature search yielded 13 studies that met the inclusion criteria including 933 LTX, 281 in trILD, and 652 in non-trILD. Despite large heterogeneity in the methodological study quality and reported outcomes among the studies, patient and graft survival after LTX in trILD did not evidently seem inferior to LTX in non-trILD. However, there may be increased risk of specific complications, such as cytopenias, airway complications, and cytomegalovirus-reactivation. Conclusions In summary, due to large heterogeneity in methodological study quality and reported outcomes, no firm conclusions can be drawn. Patient and graft survival do not seem unequivocally inferior in patients with trILD deemed eligible for LTX. On top of limited available high-quality data, specific patient selection and post-transplant management strategies may affect the currently acquired results. As such, differences may exist regarding transplant-related outcomes, which could require special attention and consideration. Further high-quality comparative studies on LTX outcomes in trILD are needed to draw final conclusions and provide recommendations regarding patient selection and post-transplantation management.
Collapse
Affiliation(s)
- Jaume Bordas-Martinez
- Erasmus MC Transplantation Institute, Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
- Centre of Excellence for Interstitial Lung Disease and Sarcoidosis, Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
- ILD Unit, Department of Respiratory Medicine, Bellvitge University Hospital, IDIBELL, Barcelona University, Hospitalet de Llobregat, CIBERES, Barcelona, Spain
| | - Jelle R. Miedema
- Centre of Excellence for Interstitial Lung Disease and Sarcoidosis, Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Bas J. Mathot
- Erasmus MC Transplantation Institute, Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Leonard Seghers
- Erasmus MC Transplantation Institute, Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Robert-Jan H. Galjaard
- Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, the Netherlands
| | | | - Anna M. Aalbers
- Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Marlies Wijsenbeek
- Centre of Excellence for Interstitial Lung Disease and Sarcoidosis, Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Maria Molina-Molina
- ILD Unit, Department of Respiratory Medicine, Bellvitge University Hospital, IDIBELL, Barcelona University, Hospitalet de Llobregat, CIBERES, Barcelona, Spain
| | - Merel E. Hellemons
- Erasmus MC Transplantation Institute, Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
- Centre of Excellence for Interstitial Lung Disease and Sarcoidosis, Department of Respiratory Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
| |
Collapse
|
2
|
He J, Hu J, Liu H. A three-gene random forest model for diagnosing idiopathic pulmonary fibrosis based on circadian rhythm-related genes in lung tissue. Expert Rev Respir Med 2023; 17:1307-1320. [PMID: 38285622 DOI: 10.1080/17476348.2024.2311262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Accepted: 01/24/2024] [Indexed: 01/31/2024]
Abstract
BACKGROUND The disorder of circadian rhythm could be a key factor mediating fibrotic lung disease Therefore, our study aims to determine the diagnostic value of circadian rhythm-related genes (CRRGs) in IPF. METHODS We retrieved the data on CRRGs from previous studies and the GSE150910 dataset. The participants from the GSE150910 dataset were divided into training and internal validation sets. Next, we used several various bioinformatics methods and machine learning algorithms to screen genes. Next, we identified SEMA5A, COL7A1, and TUBB3, which were included in the random forest (RF) diagnostic model. Finally, external validation was conducted on data retrieved from the GSE184316 datasets. RESULTS The results revealed that the RF diagnostic model could diagnose patients with IPF in the internal validation set with the area under the ROC curve (AUC) value of 0.905 and in the external validation with the AUC value of 0.767. Furthermore, real-time quantitative PCR and western blotting results revealed a significant decrease in SEMA5A (p < 0.05) expression level and an increase in COL7A1 and TUBB3 expression levels in TGF-β1-treated normal human lung fibroblasts. CONCLUSION We constructed an RF diagnostic model based on SEMA5A, COL7A1, and TUBB3 expression in lung tissue for diagnosing patients with IPF.
Collapse
Affiliation(s)
- Jie He
- Clinical Medical College of Chengdu Medical College, Chengdu, Sichuan, China
- Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China
| | - Jun Hu
- Clinical Medical College of Chengdu Medical College, Chengdu, Sichuan, China
- Department of Otolaryngology - Head and Neck Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China
| | - Hairong Liu
- Clinical Medical College of Chengdu Medical College, Chengdu, Sichuan, China
- Department of Geriatric Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China
| |
Collapse
|